Metri Bio
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Metri Bio - overview
Location
Boston, MA, US
Primary Industry
Software
About
Based in the US, Metri Bio specializes in developing innovative therapeutics for endometrial diseases, primarily focusing on conditions like endometriosis that affect millions globally. Metri Bio is engaged in creating therapeutics targeting endometrial diseases, founded in Boston, US. The company recently pivoted its strategy to focus on endometriosis, raising USD 5 million in a funding round led by Pillar on December 2, 2025. The latest investment marks the total amount raised by the company to USD 5 million, with investors including Pace Ventures Enigma, Pillar, and Slocum Management.
Metri Bio is focused on developing first-in-class therapeutics specifically for endometrial diseases, targeting conditions such as endometriosis, which affects over two billion women worldwide. The company's core product offering centers around a novel therapeutic platform designed to address the underlying mechanisms of endometriosis and related conditions, influencing immune, cardiovascular, and metabolic pathways. Metri Bio aims to establish reliable disease targets and disease-modifying treatments through its proprietary technologies, serving healthcare providers, researchers, and patients globally. Metri Bio has recently raised USD 5 million in a pre-seed funding round to support the development of its endometriosis therapeutics.
The revenue model is structured around partnerships with healthcare providers and research institutions. Their transactions may involve direct sales to medical professionals and collaborations with pharmaceutical companies for broader distribution, with pricing reflecting the specialized nature of their products. In December 2025, Metri Bio raised USD 5 million in pre-seed funding led by Pillar, with participation from Pace Ventures Enigma, Slocum Management, and Navec Investments. The company plans to utilize this funding to further develop its discovery platform and therapeutic programs, focusing on new products aimed at addressing endometrial diseases.
Additionally, Metri Bio is likely to explore new markets with a high prevalence of endometriosis, enhancing its reach and impact in the healthcare sector.
Current Investors
Pillar, Pace Ventures Enigma, Slocum Management
Primary Industry
Software
Sub Industries
Biotechnology, Oncology/Cancer Treatment, Medical Software
Website
www.metri.bio
Verticals
3D Printing, HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.